This website uses own and third-party cookies to compile statistical information on your browsing habits, so that your experience will be enhanced and personalised, providing you with contents in which you are interested. If you continue browsing this site, we shall consider that you have accepted their installation and use. You can change your settings and obtain further information at Cookies Policy

Sala de prensa

More opportunities for people
Sunday, 23 July 2017
Home » News items » A therapeutic HIV vaccine clinical trial induces viral control in 5 people without taking ...

A therapeutic HIV vaccine clinical trial induces viral control in 5 people without taking antiretroviral therapy

Barcelona, 16 de February 2017
Rueda de prensa ensayo clínico de vacuna terapéutica contra el VIH. IrsiCaixa
Add the video to your web site

Other videos of the same news item
Showing video 1 to 3 de 3
Reproducir vídeo1
Reproducir vídeo2
Reproducir vídeo3
  •  
  •  
  •  
Rueda de prensa ensayo clínico de vacuna terapéutica contra el VIH. IrsiCaixa

A clinical trial conducted by the IrsiCaixa AIDS Research Institute, supported by the Obra Social "la Caixa" and the Department of Health of the Generalitat de Catalunya, and the Fight AIDS Foundation has induced HIV control in 5 people who have been in an antiretroviral pause for 5, 13, 17, 20 and 27 weeks, respectively. Usually virus rebounds during the first 4 weeks after treatment interruption.


This is the first therapeutic intervention against HIV that has proved to be successful in reeducating the immune system of HIV-infected people, enabling it to keep the virus under control while not taking antiretroviral drugs. Now the aim of the researchers is to understand how to improve the effectiveness of this strategy in more patients.


The study, still ongoing, enrolls 15 HIV-positive people who received a therapeutic vaccine designed by researchers of the Oxford University, combined with a drug from Celgene pharmaceutical company intended to ‘awaken’ the latent virus.


The clinical trial is carried out at the Germans Trias i Pujol University Hospital (Barcelona), the Hospital Clínic-IDIBAPS of Barcelona and the community center BCN Checkpoint. IrsiCaixa sponsors the study, with funding from “la Caixa” Foundation, the Fundació Glòria Soler, the Gala Sida Barcelona and the Instituto de Salud Carlos III of the Spanish Ministry of Economy, Industry and Competitiveness, among others.


More information in the PDF press release

How to navigate this site icono_pie - Contact us icono_pie - Accessibility icono_pie  
©icono_pie Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona, "la Caixa". 2017. All rights reserved
Legal information icono_pie- Privacy policy icono_pie - Cookies Policy icono_pie - Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona, "la Caixa". icono_pie